瑞舒伐他汀对老年冠心病患者造影剂肾病的预防

Efficacy of rosuvastatin in the prevention of contrast-induced nephropathy in elderly patients with coronary heart disease

目的观察瑞舒伐他汀对老年冠心病患者造影剂肾病的预防。方法将100例老年行冠脉造影检查患者随机分为常规组和瑞舒伐他汀组,每组50例。瑞舒伐他汀组在常规治疗基础上给予瑞舒伐他汀10 mg,1次/d,睡前口服。分别于术前、术后24 h、72 h测定尿素氮(BUN)及血肌酐(Scr)水平并计算内生肌酐清除率(Ccr)。结果常规组患者术后72 h BUN、Scr水平均高于术前(P<0.05),术后72 h Ccr水平低于术前(P<0.05)。瑞舒伐他汀组术后24 h、72 h BUN及Scr、Ccr水平较术前差异无统计学意义(P>0.05)。术后瑞舒伐他汀组BUN、Scr水平均低于同期常规组(P<0.05),Ccr水平均高于同期常规组(P<0.05)。两组造影剂肾病(CIN)发病率无明显差异(P>0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论瑞舒伐他汀对老年冠心病患者造影剂肾病有一定的预防作用。

Objective To investigate the rosuvastatin in the prevention of contrast-induced nephropathy（ CIN）in elderly patients with coronary heart disease. Methods 100 elderly patients with coronary heart disease received coronary angiography were randomly divided into conventional group and rosuvastatin group,50 cases in each group. Rosuvastatin group were given 10 mg rosuvastatin orally,once a day after dinner. The levels of BUN,Scr and Ccr before and 24 hours,72 hours after contrast administration between groups were measured and compared. Results The levels of BUN and Scr in 72 hours after contrast ad-ministration in conventional group were higher than before contrast administration（P﹤0. 05）,The levels of Ccr in 72 hours after contrast administration were lower than before contrast administration（P﹤0. 05）. The levels of BUN,Scr and Ccr in 24,72 hours after contrast administration did not change in rosuvastatin group（P﹥0. 05）. The levels of BUN and Scr after contrast administra-tion in rosuvastatin group were lower than conventional group（P﹤0. 05）. The levels of Ccr in rosuvastatin group was higher than conventional group（P﹤0. 05）. There was no difference on the incidence of contrast-induced nephropathy between two groups （P﹥0. 05）. The incidences of adverse reactions between two groups were not statistically different（P﹥0. 05）. Conclusion Ro-suvastatin have a good efficacy in the prevention of contrast-induced nephropathy in elderly patients with coronary heart disease.